RPRX — Royalty Pharma plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1802768 ·
Last close
$68.68
Market Cap
$30.58B
52W High
$70.13
52W Low
$36.68
ADV30
3,378,290
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 690,103,000 | — | 561,197,000 | 144,675,000 | 19,461,223,000 | 513,657,000 | 9,665,952,000 |
| Jun 2026 | 674,141,000 | — | 133,119,000 | 17,883,000 | 19,819,771,000 | 811,986,000 | 10,034,057,000 |
| Mar 2026 | 630,576,000 | — | 632,481,000 | 294,690,000 | 19,815,415,000 | 586,395,000 | 9,878,582,000 |
| Dec 2025 | 621,990,000 | — | 388,382,000 | 214,205,000 | 19,620,780,000 | 618,696,000 | 9,905,841,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,959,918,000
Investing CF
$-1,841,052,000
Financing CF
$-1,544,153,000
CapEx
—
Dividends Paid
$-408,865,000
Buybacks
$-261,618,000
EPS Diluted TTM
$1.41
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$2,498,713,000
Inventory
—
Receivables
$35,931,000
ST Investments
$968,078,000
EBIT TTM
$1,544,296,000
Pretax Income TTM
$1,172,292,000
Interest Exp TTM
$372,004,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,616,809,984
EBITDA
$1,690,461,056
Free Cash Flow
$-450,273,632
Enterprise Value
$40,967,372,800
Total Cash
$544,857,024
Total Debt
$8,587,494,912
Shares Out
445,265,805
Trailing EPS
$1.53
Book Value
$15.34
ROE
12.1%
ROA
5.4%
Div Yield
1.40%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,378,193,000 | 1,559,518,000 | 770,947,000 | 19,620,780,000 | 9,905,841,000 | 6,476,900,000 | 2,489,823,000 |
| Dec 2024 | 2,263,576,000 | 1,292,444,000 | 858,983,000 | 18,222,715,000 | 7,880,349,000 | 6,946,581,000 | 2,768,986,000 |
| Dec 2023 | 2,354,554,000 | 1,492,150,000 | 1,134,834,000 | 16,381,851,000 | 6,297,562,000 | 6,526,497,000 | 2,987,802,000 |
| Dec 2022 | 2,237,215,000 | 922,892,000 | 42,832,000 | 16,813,466,000 | 7,288,093,000 | 5,628,150,000 | 2,143,980,000 |
TTM Snapshot
Revenues TTM
$2,535,998,000
NetIncome TTM
$814,995,000
OpCashFlow TTM
—
Assets (Latest)
$19,819,771,000
Forward EPS
$5.91
Max Pain — expiry 2026-12-18
max pain strike: $45.00 · spot: $68.67 · call oi: 4,088 · put oi: 154Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GMAB | GENMAB A/S | $31.95B | $51.96 | — |
| ROIV | Roivant Sciences Ltd. | $28.05B | $38.71 | — |
| ZTS | Zoetis Inc. | $33.92B | $83.48 | — |
| INSM | INSMED Inc | $26.73B | $121.86 | — |
| UTHR | UNITED THERAPEUTICS Corp | $24.88B | $584.10 | — |
News headlines (Yahoo Finance, 1h cache)
Royalty Pharma to present at the UBS Global Biopharma Conference
2026-11-12 21:15 · Yahoo
3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them
2026-11-10 13:47 · Yahoo
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug
2026-11-08 15:35 · Yahoo
How Investors Are Reacting To Royalty Pharma (RPRX) Earnings Beat
2026-11-06 22:14 · Yahoo
Royalty Pharma (RPRX) Upgraded to Buy: What Does It Mean for the Stock?
2026-11-06 16:00 · Yahoo
Royalty Pharma (RPRX) Stock Looks Fully Valued After A 168% Run
2026-11-06 08:15 · Yahoo
Can Royalty Pharma (RPRX) Justify Its Price Following A Third Straight Guidance Raise?
2026-11-06 01:18 · Yahoo
Royalty Pharma PLC (RPRX) (Q3 2026) Earnings Call Highlights: Raised Guidance, Strong Royalty ...
2026-11-05 01:06 · Yahoo
Royalty Pharma plc Q3 2026 Earnings Call Summary
2026-11-04 23:21 · Yahoo
Royalty Pharma Q3 Earnings Call Highlights
2026-11-04 20:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.